| 名稱 | Human ADORA3 Ga15/CHO |
| 型號 | CBP71338 |
| 報價 | ![]() |
| 特點 | Human ADORA3 Ga15/CHO 凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 【產(chǎn)品推介】CD47&SIRPɑ 細(xì)胞篩選模型
- 黃金賽道——CDH17靶點
- CD74-ROS1的藥靶模型+DNARNA標(biāo)準(zhǔn)品+ddPCR試劑盒
- 細(xì)胞株定期維護(hù)與監(jiān)測要做好哪些?
- 【產(chǎn)品推介】NRAS診斷標(biāo)準(zhǔn)品
- 細(xì)胞因子風(fēng)暴和自身免疫性炎癥治療新靶點GM-CSF
- GARP/LTGF-β細(xì)胞模型簡介
- JAK2激酶抑制劑細(xì)胞篩選模型
- CYP2C9基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- 人結(jié)腸癌細(xì)胞株為何多取上皮細(xì)胞樣?
聯(lián)系我們
電話:4008750250
號碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > GPCR細(xì)胞株 > CBP71338Human ADORA3 Ga15/CHO
- 詳細(xì)內(nèi)容
| CBP71338 | |
| I. Background | |
Extracellular adenosine mediates a multitude of biological effects, including wakefulness, antiarrythmia, bronchoconstriction and response to ischemia and oxidative stress. A family of four G-protein coupled adrenoceptors, A1, A2A, A2B and A3, is responsible for these effects. A3, which couples to Gi/o, is expressed in a wide range of human tissues, but most predominantly in the lung and liver. Recent animal model studies have shown that A3 receptors play important roles in brain ischemia, immunosuppresion, and bronchospasm. A3 receptor agonists and/or agonists may have important clinical value in the treatment of asthma and inflammation. Mice lacking A3 receptors display reduced mast cell degranulation and bronchoconstriction in response to adenosine. | |
| II. Introduction | |
| Host Cell: | CHO |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | F12K+10% FBS+2 μg/ml puromycin+ 100 μg/ml Hygromycin B |
| Mycoplasma Status: | Negative |
| Storage: | Liquid nitrogen immediately upon delivery |
| Application(s): | Functional assays for ADORA3 receptor |
| Transducer: | Gi |
| Ⅲ. Description of Host Cell Line | |
| Organism: | Hamster |
| Tissue: | Ovary |
| Morphology: | Epithelial |
| Growth Properties: | Adherent |
| Ⅳ. Representative Data | |




